- A practical approach to statin intolerance2015 | First Faculty of Medicine
- Terapie inhibitory PCSK9 u pacientů se statinovou intolerancí2019 | First Faculty of Medicine
- Až příliš obávaná statinová intolerance2017 | Second Faculty of Medicine
- Statin intolerance - finding practical solutions2017 | First Faculty of Medicine
- Alirocumab, Praluent(R) in the light of studies2016 | First Faculty of Medicine
- Food supplements in dyslipidemia therapy - ArmoLIPID PLU2017 | First Faculty of Medicine
- PCSK9 inhibition as the new hope for patients with familial hypercholesterolemia, statin intolerance and eventually for those at the highest cardiovascular risk? Focused on alirocumab, Praluent(R)2015 | First Faculty of Medicine
- Komentář k "Praktickému doporučení pro použití PCSK9-inhibitorů" aneb Proč renomovaní autoři píší dokumenty, které si samy odporují2018 | First Faculty of Medicine
- Why do we fail when treating dyslipidemia? +12018 | First Faculty of Medicine
- Význam ezetimibu pro intervenci hyperlipidemie u pacientů s DM2016 | First Faculty of Medicine
- Statin-associated myopathy: clinical guideline of Slovak Atherosclerosis Association and Czech Society for Atherosclerosis2016 | First Faculty of Medicine, Central Library of Charles University
- Alirocumab in treatment of combined dyslipidemia2020 | Third Faculty of Medicine
- New options in diagnostics and treatment of familial hypercholesterolemia2018 | First Faculty of Medicine
